1. Home
  2. ICCC vs RNLX Comparison

ICCC vs RNLX Comparison

Compare ICCC & RNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ICCC
  • RNLX
  • Stock Information
  • Founded
  • ICCC 1982
  • RNLX 2018
  • Country
  • ICCC United States
  • RNLX United States
  • Employees
  • ICCC N/A
  • RNLX N/A
  • Industry
  • ICCC Biotechnology: Pharmaceutical Preparations
  • RNLX Medical Specialities
  • Sector
  • ICCC Health Care
  • RNLX Health Care
  • Exchange
  • ICCC Nasdaq
  • RNLX Nasdaq
  • Market Cap
  • ICCC 35.4M
  • RNLX 32.8M
  • IPO Year
  • ICCC 1987
  • RNLX 2020
  • Fundamental
  • Price
  • ICCC $4.16
  • RNLX $0.29
  • Analyst Decision
  • ICCC
  • RNLX
  • Analyst Count
  • ICCC 0
  • RNLX 0
  • Target Price
  • ICCC N/A
  • RNLX N/A
  • AVG Volume (30 Days)
  • ICCC 6.2K
  • RNLX 5.0M
  • Earning Date
  • ICCC 08-08-2024
  • RNLX 05-15-2024
  • Dividend Yield
  • ICCC N/A
  • RNLX N/A
  • EPS Growth
  • ICCC N/A
  • RNLX N/A
  • EPS
  • ICCC N/A
  • RNLX N/A
  • Revenue
  • ICCC $21,282,719.00
  • RNLX $2,221,000.00
  • Revenue This Year
  • ICCC N/A
  • RNLX $48.40
  • Revenue Next Year
  • ICCC N/A
  • RNLX $104.00
  • P/E Ratio
  • ICCC N/A
  • RNLX N/A
  • Revenue Growth
  • ICCC 32.89
  • RNLX N/A
  • 52 Week Low
  • ICCC $4.05
  • RNLX $0.22
  • 52 Week High
  • ICCC $5.75
  • RNLX $3.66
  • Technical
  • Relative Strength Index (RSI)
  • ICCC 42.25
  • RNLX 40.38
  • Support Level
  • ICCC $4.10
  • RNLX $0.28
  • Resistance Level
  • ICCC $4.29
  • RNLX $0.35
  • Average True Range (ATR)
  • ICCC 0.11
  • RNLX 0.04
  • MACD
  • ICCC -0.00
  • RNLX 0.01
  • Stochastic Oscillator
  • ICCC 13.04
  • RNLX 22.90

About ICCC ImmuCell Corporation

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.

About RNLX Renalytix plc

Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Share on Social Networks: